AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

They display ... Second Phase 3 Clinical Trial Again Shows Dupilumab Lessens Disease in COPD Patients With Type 2 Inflammation May 20, 2024 — Chronic obstructive pulmonary disease patients with ...

However, it can sometimes cause lower respiratory infections like pneumonia, asthma flare-ups or make chronic obstructive pulmonary disease (COPD) worse. HMPV infections are more common in the ...

Background: Information about the influence of regular physical activity on the course of chronic obstructive pulmonary disease (COPD) is scarce. A study was undertaken to examine the association ...

More information: Screening Patients for Physical Inactivity Helps Identify Patients at Risk for Cardiometabolic and Chronic Diseases, Preventing Chronic Disease (2024). Lucas J. Carr et al ...

Four survived with chronic pulmonary disease. One of those who survived is still symptomatic, with diffuse, faint rales bilaterally, mild subcostal retraction and slight cyanosis when crying.

2024 brought some major advancements in medicine. That includes the approval of "innovative" drugs like Tryvio for high blood pressure, Neffy for severe allergic reactions and Dupixent for chronic ...

In early December, international alarm bells went off because of a mysterious disease circulating in a remote part of the Democratic Republic of Congo. The Africa Centers for Disease Control and ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

Objective To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler, ...